Article thumbnail

Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes

By Eduardo Pimenta and Suzanne Oparil


The vascular endothelium, the largest “organ” in the body, synthesizes and releases a wide spectrum of vasoactive substances into the circulation. Endothelial dysfunction links hypertension and other cardiovascular (CV) risk factors that promote the development of atherosclerotic plaque, CV disease, and fatal and nonfatal CV events. Blood pressure (BP) reduction is the most effective way to reduce CV risk in patients with hypertension, but it is unknown whether endothelial dysfunction is a cause or consequence of hypertension. Renin–angiotensin–aldosterone system blockers improve endothelial function and have favorable vascular, metabolic, cardiac, and renoprotective effects that are independent of BP reduction. Olmesartan effectively reduces BP and also has vasoprotective properties, including reductions in endothelial dysfunction and inflammation, prevention of microalbuminuria, and reversal of vascular remodeling. Large-scale, long-term studies are needed to confirm that olmesartan has vasoprotective effects that are independent of BP control and to determine whether these pleiotropic effects translate into improved CV disease outcomes

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension.
  2. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress.
  3. Angiotensin II receptor antagonists.
  4. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
  5. Basal nitric oxide production is impaired in offspring of patients with essential hypertension.
  6. (1997). Basal nitric oxide synthesis in essential hypertension. Lancet.
  7. but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
  8. captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
  9. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
  10. (2007). Carotid intima-media thickness and plaque volume changes following 2-year angiotensin IIreceptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis.
  11. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk.
  12. (2001). Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
  13. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
  14. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
  15. (2003). Development and progression of nephropathy
  16. diagnosis and prognostic implications of endothelial dysfunction.
  17. (2008). Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol.
  18. (2009). Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag.
  19. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
  20. Endothelial function and dysfunction: testing and clinical relevance.
  21. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension.
  22. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension.
  23. (1992). Endotheliumdependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol.
  24. Etiology and pathogenesis of systemic hypertension.
  25. (1996). Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med.
  26. (2006). Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J.
  27. (2008). Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag.
  28. Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
  29. Hypertension causes premature aging of endothelial function in humans.
  30. Impact of olmesartan on progression of coronary atherosclerosis: a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
  31. (1995). Impaired endotheliumdependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance
  32. impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial.
  33. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.
  34. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.
  35. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.
  36. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation.
  37. luscher TF. Endothelium in hypertension:nitric oxide.
  38. Mechanical factors in arterial aging: a clinical perspective.
  39. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications.
  40. (2006). Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem.
  41. Nitric oxide in hypertension.
  42. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.
  43. (2001). Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res.
  44. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects.
  45. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
  46. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
  47. Prognostic value of coronary vascular endothelial dysfunction.
  48. Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors.
  49. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens.
  50. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).
  51. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
  52. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.
  53. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
  54. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population.
  55. Vascular endothelial cells synthesize nitric oxide from L-arginine.